Roche takes on pricey rivals as FDA approves SMA drug
pharmaphorum
AUGUST 10, 2020
While this is not cheap by anybody’s reckoning, Roche hopes that the less intimidating price tag, plus the patient-friendly oral administration method will give it a competitive edge. Evrysdi also improved survival without permanent ventilation at 12 and 23 months, compared to natural history.
58 
Let's personalize your content